destination therapy

destination therapy

The use of permanently implanted left ventricular assist devices to treat patients with severe end-stage heart failure. Destination therapy is typically employed for patients who either are deemed poor candidates for heart transplantation or for those who cannot obtain a heart for transplantation as a result of a shortage of organs.
References in periodicals archive ?
Consequently, a growing number of HF patients now depend on state-of-the-art continuous flow Left Ventricular Assist Devices (cf-LVAD) as a bridge to transplant or as a means of destination therapy.
The device is also currently the subject of a US clinical trial for destination therapy.
The company's LVADs are used to treat end-stage CHF in three ways that include bridge-to-transplant, bridge-to-recovery, and destination therapy.
The first 366 randomised patients will be followed for 24 months to evaluate a long-term indication such as Destination Therapy.
10,11) A third generation pump with a continuous-flow, centrifugal design currently used as a bridge-to-transplant is now undergoing research trials for use as a destination therapy LVAD.
What sets the Fortis Centre apart is its designation as a Ventricular Assist Device (VAD) Destination Therapy Centre, a bridge to a transplant in case it is required later.
Apaxis Medical's LVADs are currently used to treat end-stage CHF in three ways that include bridge-to-transplant (BTT), bridge-to-recovery (BTR), and destination therapy (DT).
The results of the Phase 2 trial assessing the safety and efficacy of injecting a single dose of MPCs directly into the heart muscle of end-stage heart failure patients receiving an LVAD for either bridge-to-transplant or as a destination therapy were presented on 18 November at the American Heart Association Scientific Sessions.
Tucson, AZ, announced the US Food and Drug Administration (FDA) has approved two Humanitarian Use Device (HUD) designations for its new 50cc Total Artificial Heart to be used for destination therapy and pediatric bridge to transplant.
However, the HeartWare pump is currently under evaluation for destination therapy in the randomized multicenter trial ENDURANCE.
It is a destination therapy for patients who can't find a donor or may not survive a transplant and offers many advantages.
Since 2002, LVADs have been considered destination therapy (DT) for patients who are ineligible for transplant as well as for patients with estimated 1-year mortality greater than 50% with medical therapy (Grady & Shinn, 2008).